A synthetic pentadecapeptide (15 amino acids) derived from a protein found in human gastric juice. One of the most extensively studied research peptides in the preclinical literature, with documented effects across gastrointestinal healing, tendon and ligament repair, muscle recovery, angiogenesis, peripheral nerve repair, and vascular stabilization. Frequently studied alongside TB-500 in the Wolverine Stack.
For state-by-state regulatory and compounding context relevant to research peptides, consult the Peptide Laws by State hub.
For the regulatory discussion specific to BPC-157 and other compounds considered by the FDA advisory panel, read FDA Advisory Panel Votes to Recommend BPC-157, TB-500, KPV, and MOTS-c for Compounding.
What Is BPC-157?
BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide — 15 amino acids — derived from a naturally occurring protein in human gastric juice. First isolated in the early 1990s, its stability in gastric acid and remarkable tissue-healing properties across multiple organ systems have made it one of the most extensively studied research peptides in the field.
Mechanism of Action
BPC-157 operates through several converging mechanisms. It stimulates angiogenesis by upregulating VEGFR2 and activating the FAK-paxillin pathway. It accelerates wound healing by increasing expression of growth factor receptors on fibroblasts and tendon cells. It modulates the nitric oxide system — a key regulator of blood flow, inflammation, and tissue repair — and demonstrates strong anti-inflammatory activity by suppressing COX-2 and NF-κB pathways. Uniquely, BPC-157 retains stability in gastric acid that most peptides lack.
Musculoskeletal Research
BPC-157 has been studied extensively in tendon healing models. Studies show accelerated collagen organization, fibroblast migration, and tendon tensile strength restoration following injury. Similar effects have been demonstrated in ligament, muscle, and bone healing models.
Gastrointestinal and Neurological Research
BPC-157's gastric origin gives it particular activity in the GI tract. It has demonstrated efficacy in animal models of inflammatory bowel disease, gastric ulcers, and short bowel syndrome. Neurologically, it has shown neuroprotective effects in models of traumatic brain injury, spinal cord injury, and dopaminergic system disruption.
Quick Reference
| Literature-Reported Dose Range | 250-500 mcg |
| Literature-Reported Frequency | 1-2x daily |
| Literature-Reported Cycle Length | 4-12 weeks |
| Literature-Reported Washout | 4+ weeks |
| Storage | Fridge, 30 days |
| Sites Reported in Studies | Belly, thigh, arm |
| Timing | Empty stomach |
Research Indications
Gastrointestinal
Ulcer Protection
Studies demonstrate protective effects against gastric and duodenal ulcers through cytoprotective mechanisms.
Intestinal Repair
Research shows acceleration of intestinal healing and reduction of inflammatory markers in IBD models.
Mucosal Healing
Evidence supports enhanced mucosal barrier function and accelerated epithelial regeneration.
Wound Healing
Tendon Healing
Accelerated tendon-to-bone healing and improved biomechanical properties in injury models.
Muscle Recovery
Enhanced muscle healing and reduced recovery time following crush injuries and surgical procedures.
Angiogenesis
Promotes blood vessel formation and improves vascularization in healing tissues.
Neurological
Neuroprotection
Protective effects against various neurotoxic agents and ischemic brain injury models.
Spinal Cord Injury
Improved functional recovery and reduced tissue damage in spinal cord injury studies.
Peripheral Nerves
Enhanced peripheral nerve regeneration and functional recovery after injury.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| General healing | 250-500mcg | 1-2x daily | SubQ or IM |
| Serious injury | 500-1000mcg | 2x daily | SubQ near injury |
| Gastric issues | 500mcg-1mg | 1-2x daily | Oral (empty stomach) |
| Maintenance | 250mcg | 1x daily | SubQ |
Timing
Recommended administration window: empty stomach. Typical onset: 1-3 weeks.
Peptide Interactions
This pairing includes GH/IGF-axis signaling. Published evidence for the exact combination is limited; define exposure timing and monitor protocol-relevant endocrine and tolerability endpoints rather than assuming additive benefit.
These compounds address different research mechanisms represented in this preset. This is mechanistic complementarity, not evidence of clinical synergy: controlled studies of the exact combination are limited or unavailable, so interpret each exposure and safety signal independently.
These compounds address different research mechanisms represented in this preset. This is mechanistic complementarity, not evidence of clinical synergy: controlled studies of the exact combination are limited or unavailable, so interpret each exposure and safety signal independently.
These compounds address different research mechanisms represented in this preset. This is mechanistic complementarity, not evidence of clinical synergy: controlled studies of the exact combination are limited or unavailable, so interpret each exposure and safety signal independently.
These compounds address different research mechanisms represented in this preset. This is mechanistic complementarity, not evidence of clinical synergy: controlled studies of the exact combination are limited or unavailable, so interpret each exposure and safety signal independently.
This pairing includes GH/IGF-axis signaling. Published evidence for the exact combination is limited; define exposure timing and monitor protocol-relevant endocrine and tolerability endpoints rather than assuming additive benefit.
These compounds address different research mechanisms represented in this preset. This is mechanistic complementarity, not evidence of clinical synergy: controlled studies of the exact combination are limited or unavailable, so interpret each exposure and safety signal independently.
The components have different research mechanisms and may be scheduled around training, feeding, or metabolic assessments. Evidence for the exact combination is limited, so timing should be documented to avoid confounding endpoint interpretation.
The components have different research mechanisms and may be scheduled around training, feeding, or metabolic assessments. Evidence for the exact combination is limited, so timing should be documented to avoid confounding endpoint interpretation.
These compounds address different research mechanisms represented in this preset. This is mechanistic complementarity, not evidence of clinical synergy: controlled studies of the exact combination are limited or unavailable, so interpret each exposure and safety signal independently.
The components have different research mechanisms and may be scheduled around training, feeding, or metabolic assessments. Evidence for the exact combination is limited, so timing should be documented to avoid confounding endpoint interpretation.
These compounds address different research mechanisms represented in this preset. This is mechanistic complementarity, not evidence of clinical synergy: controlled studies of the exact combination are limited or unavailable, so interpret each exposure and safety signal independently.
These compounds address different research mechanisms represented in this preset. This is mechanistic complementarity, not evidence of clinical synergy: controlled studies of the exact combination are limited or unavailable, so interpret each exposure and safety signal independently.
These compounds address different research mechanisms represented in this preset. This is mechanistic complementarity, not evidence of clinical synergy: controlled studies of the exact combination are limited or unavailable, so interpret each exposure and safety signal independently.
These compounds address different research mechanisms represented in this preset. This is mechanistic complementarity, not evidence of clinical synergy: controlled studies of the exact combination are limited or unavailable, so interpret each exposure and safety signal independently.
This pairing includes GH/IGF-axis signaling. Published evidence for the exact combination is limited; define exposure timing and monitor protocol-relevant endocrine and tolerability endpoints rather than assuming additive benefit.
These compounds address different research mechanisms represented in this preset. This is mechanistic complementarity, not evidence of clinical synergy: controlled studies of the exact combination are limited or unavailable, so interpret each exposure and safety signal independently.
No known negative interactions
BPC-157 upregulates GH receptors, enhancing CJC-1295 effectiveness for tissue repair
No known interactions - different mechanisms of action and receptor targets
Safe combination - BPC-157 promotes tissue repair via growth factors, AOD-9604 targets fat metabolism via beta-3 adrenergic receptors. No pathway overlap. Often combined in regenerative protocols.
Reported Research Timeline
01Week 1–2 (reported in cited studies): reduced inflammation markers
02Week 2–4 (reported in cited studies): improved healing rate
03Week 4–8 (reported in cited studies): maximum benefits
Side effects (reported in cited studies): usually minimal
Most common (reported in cited studies): injection site redness
Complementary healing and regeneration — BPC-157 drives angiogenesis and tissue repair while GHK-Cu promotes collagen synthesis and wound remodeling. One of the most popular healing stack combinations.
Complementary anti-inflammatory mechanisms — BPC-157 promotes tissue repair and angiogenesis while KPV suppresses NF-κB-driven inflammation. Particularly effective for gut healing protocols.
Immune regulation combined with tissue repair — TA-1 normalizes immune signaling while BPC-157 repairs damaged tissue. Used together in chronic inflammation and post-injury recovery protocols.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
May lower blood pressure slightly
Consult doctor if on blood thinners due to angiogenesis effects
Not recommended during pregnancy or breastfeeding
WADA prohibited (S0: Non-Approved Substances) - not for competitive athletes
Seek Medical Attention If:
Persistent injection site reactions
Severe headaches or dizziness
Always consult your provider
Quality Indicators
Verified Marker
White, Fluffy Cake
Lyophilized powder should appear as a white, fluffy "cake" that fills most of the vial bottom. This indicates proper freeze-drying.
Verified Marker
Clear Solution After Reconstitution
When properly mixed with BAC water, solution should be crystal clear with no particles or cloudiness.
Acceptable Range
Slight Clumping
Small clumps that dissolve completely with gentle swirling are acceptable. Shipping can cause minor compaction.
Quality Concern
Collapsed or Melted Appearance
If powder appears collapsed, melted, or stuck to vial sides, it may have been exposed to heat during shipping.
Quality Concern
Cloudy After Reconstitution
Persistent cloudiness, particles, or precipitates after gentle mixing indicate degraded or contaminated peptide.
Research Citations
- Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review
Jóźwiak, M., Bauer, M., Kamysz, W., Kleczkowska, P., 2025, Pharmaceuticals - Stable Gastric Pentadecapeptide BPC 157 and Wound Healing
Seiwerth, S., Milavic, M., Vukojevic, J., et al., 2021, Frontiers in Pharmacology - Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation
Hsieh, M.J., Liu, H.T., Wang, C.N., et al., 2017, Journal of Molecular Medicine - Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth
Staresinic, M., Sebecic, B., Patrlj, L., et al., 2003, Journal of Orthopaedic Research - The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration
Chang, C.H., Tsai, W.C., Lin, M.S., Hsu, Y.H., Pang, J.H., 2011, Journal of Applied Physiology - Effective therapy of transected quadriceps muscle in rat: Gastric pentadecapeptide BPC 157
Staresinic, M., Petrovic, I., Novinscak, T., et al., 2006, Journal of Orthopaedic Research - Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract
Sikiric, P., Seiwerth, S., Rucman, R., et al., 2011, Current Pharmaceutical Design - Stable Gastric Pentadecapeptide BPC 157, Robert's Stomach Cytoprotection
Sikiric, P., Hahm, K.B., Blagaic, A.B., et al., 2020, Gut and Liver - Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157
He, L., Feng, D., Guo, H., et al., 2022, Frontiers in Pharmacology - Pentadecapeptide BPC 157 and the central nervous system
Vukojevic, J., Milavić, M., Perović, D., et al., 2022, Neural Regeneration Research - Stable gastric pentadecapeptide BPC 157 can improve the healing course of spinal cord injury and lead to functional recovery in rats
Perovic, D., Kolenc, D., Bilic, V., et al., 2019, Journal of Orthopaedic Surgery and Research - Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds
Xu, C., Sun, L., Ren, F., et al., 2020, Regulatory Toxicology and Pharmacology
Gut healing, Tendon repair, Wound healing, Anti-inflammatory, Neuroprotection, Angiogenesis